Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FRNVU
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
HuAb3v2-CZ
|
|||||
| Synonyms |
huAb3v2 CZ; huAb3v2CZ
Click to Show/Hide
|
|||||
| Organization |
AbbVie, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.5
|
|||||
| Structure |
|
|||||
| Antibody Name |
huAb3v2
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen (CD276)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
huAb3v2-CZ linker
|
|||||
| Combination Type |
AbbVie's CZ
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.49 nM | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the H847 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
|
||||
| In Vitro Model | Lung small cell carcinoma | NCI-H847 cells | CVCL_1596 | ||